+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Malignant Mesothelioma Market by Treatment Type (Chemotherapy, Immunotherapy, Radiotherapy), Drug Class (Antifolates, Immune Checkpoint Inhibitors, Kinase Inhibitors), Line Of Therapy, Route Of Administration, End User - Global Forecast 2025-2030- Product Image
Malignant Mesothelioma Market by Treatment Type (Chemotherapy, Immunotherapy, Radiotherapy), Drug Class (Antifolates, Immune Checkpoint Inhibitors, Kinase Inhibitors), Line Of Therapy, Route Of Administration, End User - Global Forecast 2025-2030- Product Image
Sale

Malignant Mesothelioma Market by Treatment Type (Chemotherapy, Immunotherapy, Radiotherapy), Drug Class (Antifolates, Immune Checkpoint Inhibitors, Kinase Inhibitors), Line Of Therapy, Route Of Administration, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 186 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5889052
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The malignant mesothelioma market is undergoing significant transformation as new diagnostics and therapies reshape patient care, investment priorities, and competitive dynamics. Senior leaders now face evolving challenges and opportunities tied to innovation, global policy shifts, and market entry strategies.

Market Snapshot: Malignant Mesothelioma Market Overview

The Malignant Mesothelioma Market grew from USD 834.43 million in 2024 to USD 905.16 million in 2025. It is expected to continue growing at a CAGR of 8.32%, reaching USD 1.34 billion by 2030. Early-stage diagnosis remains rare, driving demand for multidisciplinary care models and ensuring continuous growth. Shifting epidemiology, driven by past occupational exposures and emerging genetic insights, maintains broad therapeutic and policy interest across key geographies.

Scope & Segmentation

This comprehensive report evaluates the full spectrum of malignant mesothelioma therapeutics, with in-depth segmentation and regional perspectives.

  • Treatment Types: Chemotherapy, Immunotherapy, Radiotherapy, Surgery, Targeted Therapy
  • Chemotherapy Regimens: Pemetrexed combinations, Platinum monotherapy
  • Immunotherapy Modalities: CTLA-4 inhibitors, PD-1 inhibitors
  • Targeted Therapeutics: EGFR inhibitors, Mesothelin-targeted agents, VEGF inhibitors
  • Drug Classes: Antifolates, Immune checkpoint inhibitors (CTLA-4, PD-1, PD-L1), Kinase inhibitors, Monoclonal antibodies, Platinum compounds
  • Lines of Therapy: First line, Second line, Third line and beyond
  • Routes of Administration: Intraperitoneal, Intravenous, Oral
  • End Users: Ambulatory surgical centers, Hospitals, Specialty clinics
  • Geographical Coverage: Americas (including United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (e.g., United Kingdom, Germany, France, Saudi Arabia, South Africa), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, and others)
  • Leading Companies Analysed: Bristol-Myers Squibb Company, Eli Lilly and Company, AstraZeneca PLC, Merck & Co., Inc., F. Hoffmann-La Roche Ltd., Pfizer Inc., Johnson & Johnson, Novartis AG, Takeda Pharmaceutical Company Limited, Sanofi S.A.

Key Takeaways for Senior Decision-Makers

  • Immuno-oncology advances are challenging established treatment protocols, expanding the arsenal beyond platinum-based regimens.
  • Combination strategies—especially those integrating immunotherapy with chemotherapy—are driving new standards of care and improving patient outcomes.
  • Adoption of targeted therapeutics is accelerating, supported by biomarker profiling and regulatory flexibility around orphan and breakthrough designations.
  • Cross-border industry collaborations, including co-development and contract manufacturing partnerships, are reducing development risk and supporting faster commercialization.
  • Regional nuances in reimbursement, regulatory review, and healthcare infrastructure require customized strategies for market access and patient engagement.
  • Data-driven value demonstration and real-world outcomes will be essential for navigating payer negotiations and sustaining long-term growth.

Tariff Impact: Effects of U.S. Trade Policies on Mesothelioma Therapeutics

Recent U.S. tariffs on pharmaceutical ingredients and active compounds may increase production costs and disrupt supply chain stability for both generic and novel mesothelioma agents. These policy shifts could prompt budgetary adjustments for healthcare providers and trial sponsors, as well as potential renegotiations between suppliers and payers. Ensuring product continuity may necessitate new domestic manufacturing investments and diversified sourcing to mitigate such risks.

Methodology & Data Sources

This report employs a robust methodology: systematic literature review, regulatory analysis, and engagement with thoracic oncology experts. Qualitative stakeholder interviews are complemented by secondary sources such as clinical trial registries and patent databases. Quantitative modeling and sensitivity analysis ensure all findings are validated and actionable.

Why This Report Matters

  • Strategic insights empower decision-makers to adapt quickly amid regulatory, clinical, and policy-driven shifts in the mesothelioma market.
  • Comprehensive segmentation supports targeted investment and resource allocation by revealing drivers and barriers within therapy classes and regions.
  • Stakeholder-focused analysis delivers a clear view into payer, provider, and manufacturer priorities, supporting effective go-to-market plans.

Conclusion

This report provides senior leaders with the actionable intelligence to align strategy, resources, and partnerships in a complex malignant mesothelioma landscape. Effective adaptation to clinical innovation, policy changes, and regional trends will define future success in this evolving oncology field.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Novel immunotherapy combinations showing improved survival in malignant mesothelioma patients
5.2. Adoption of mesothelin-targeted antibody-drug conjugates in late-stage clinical trials
5.3. Emergence of personalized treatment strategies leveraging genomic profiling in mesothelioma
5.4. Increasing utilization of dual checkpoint inhibitors in frontline mesothelioma treatment regimens
5.5. Growing pipeline of CAR T cell therapies targeting mesothelin for mesothelioma management
5.6. Rising focus on early diagnostic biomarkers and liquid biopsy technology in mesothelioma
5.7. Advances in photodynamic therapy applications for unresectable malignant mesothelioma
5.8. Development of multimodal treatment protocols integrating surgery radiation and systemic therapy
5.9. Heightened awareness of asbestos exposure litigation impact on mesothelioma patient enrollment
5.10. Expansion of real world evidence data sets informing treatment guidelines and reimbursement
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Malignant Mesothelioma Market, by Treatment Type
8.1. Introduction
8.2. Chemotherapy
8.2.1. Pemetrexed Combinations
8.2.2. Platinum Monotherapy
8.3. Immunotherapy
8.3.1. Ctla-4 Inhibitors
8.3.2. Pd-1 Inhibitors
8.4. Radiotherapy
8.5. Surgery
8.6. Targeted Therapy
8.6.1. Egfr Inhibitors
8.6.2. Mesothelin Targeted Agents
8.6.3. Vegf Inhibitors
9. Malignant Mesothelioma Market, by Drug Class
9.1. Introduction
9.2. Antifolates
9.3. Immune Checkpoint Inhibitors
9.3.1. Ctla-4 Inhibitors
9.3.2. Pd-1 Inhibitors
9.3.3. Pd-l1 Inhibitors
9.4. Kinase Inhibitors
9.5. Monoclonal Antibodies
9.6. Platinum Compounds
10. Malignant Mesothelioma Market, by Line Of Therapy
10.1. Introduction
10.2. First Line
10.3. Second Line
10.4. Third Line And Beyond
11. Malignant Mesothelioma Market, by Route Of Administration
11.1. Introduction
11.2. Intraperitoneal
11.3. Intravenous
11.4. Oral
12. Malignant Mesothelioma Market, by End User
12.1. Introduction
12.2. Ambulatory Surgical Centers
12.3. Hospitals
12.4. Specialty Clinics
13. Americas Malignant Mesothelioma Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Malignant Mesothelioma Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Malignant Mesothelioma Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Bristol-Myers Squibb Company
16.3.2. Eli Lilly and Company
16.3.3. AstraZeneca PLC
16.3.4. Merck & Co., Inc.
16.3.5. F. Hoffmann-La Roche Ltd.
16.3.6. Pfizer Inc.
16.3.7. Johnson & Johnson
16.3.8. Novartis AG
16.3.9. Takeda Pharmaceutical Company Limited
16.3.10. Sanofi S.A.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. MALIGNANT MESOTHELIOMA MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2030 (%)
FIGURE 10. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. MALIGNANT MESOTHELIOMA MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. MALIGNANT MESOTHELIOMA MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. MALIGNANT MESOTHELIOMA MARKET: RESEARCHAI
FIGURE 26. MALIGNANT MESOTHELIOMA MARKET: RESEARCHSTATISTICS
FIGURE 27. MALIGNANT MESOTHELIOMA MARKET: RESEARCHCONTACTS
FIGURE 28. MALIGNANT MESOTHELIOMA MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. MALIGNANT MESOTHELIOMA MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PEMETREXED COMBINATIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PEMETREXED COMBINATIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PLATINUM MONOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PLATINUM MONOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY SURGERY, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY SURGERY, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY MESOTHELIN TARGETED AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY MESOTHELIN TARGETED AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY VEGF INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY VEGF INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ANTIFOLATES, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ANTIFOLATES, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY KINASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PLATINUM COMPOUNDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PLATINUM COMPOUNDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY INTRAPERITONEAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY INTRAPERITONEAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 125. CANADA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 126. CANADA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 127. CANADA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 128. CANADA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 129. CANADA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 130. CANADA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 131. CANADA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 132. CANADA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 133. CANADA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 134. CANADA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 135. CANADA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 136. CANADA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 137. CANADA MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 138. CANADA MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 139. CANADA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 140. CANADA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 141. CANADA MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 142. CANADA MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 143. MEXICO MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 144. MEXICO MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 145. MEXICO MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 146. MEXICO MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 147. MEXICO MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 148. MEXICO MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 149. MEXICO MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 150. MEXICO MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 151. MEXICO MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 152. MEXICO MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 153. MEXICO MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 154. MEXICO MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 155. MEXICO MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 156. MEXICO MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 157. MEXICO MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 158. MEXICO MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 159. MEXICO MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 160. MEXICO MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 161. BRAZIL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 162. BRAZIL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 163. BRAZIL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 164. BRAZIL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 165. BRAZIL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 166. BRAZIL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 167. BRAZIL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 168. BRAZIL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 169. BRAZIL MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 170. BRAZIL MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 171. BRAZIL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 172. BRAZIL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 173. BRAZIL MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 174. BRAZIL MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 175. BRAZIL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 176. BRAZIL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 177. BRAZIL MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 178. BRAZIL MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 179. ARGENTINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 180. ARGENTINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 181. ARGENTINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 182. ARGENTINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 183. ARGENTINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 184. ARGENTINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 185. ARGENTINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 186. ARGENTINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 187. ARGENTINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 188. ARGENTINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 189. ARGENTINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 190. ARGENTINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 191. ARGENTINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 192. ARGENTINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 193. ARGENTINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 194. ARGENTINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 195. ARGENTINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 196. ARGENTINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 215. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 216. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 217. UNITED KINGDOM MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 218. UNITED KINGDOM MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 219. UNITED KINGDOM MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 220. UNITED KINGDOM MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 221. UNITED KINGDOM MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 222. UNITED KINGDOM MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 223. UNITED KINGDOM MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 224. UNITED KINGDOM MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 225. UNITED KINGDOM MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 226. UNITED KINGDOM MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 227. UNITED KINGDOM MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 228. UNITED KINGDOM MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 229. UNITED KINGDOM MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 230. UNITED KINGDOM MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 232. UNITED KINGDOM MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 234. UNITED KINGDOM MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 235. GERMANY MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 236. GERMANY MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 237. GERMANY MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 238. GERMANY MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 239. GERMANY MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 240. GERMANY MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 241. GERMANY MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 242. GERMANY MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 243. GERMANY MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 244. GERMANY MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 245. GERMANY MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 246. GERMANY MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 247. GERMANY MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 248. GERMANY MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 249. GERMANY MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 250. GERMANY MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 251. GERMANY MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 252. GERMANY MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 253. FRANCE MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 254. FRANCE MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 255. FRANCE MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 256. FRANCE MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 257. FRANCE MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 258. FRANCE MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 259. FRANCE MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 260. FRANCE MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 261. FRANCE MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 262. FRANCE MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 263. FRANCE MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 264. FRANCE MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 265. FRANCE MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 266. FRANCE MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 267. FRANCE MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 268. FRANCE MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 269. FRANCE MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 270. FRANCE MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 271. RUSSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 272. RUSSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 273. RUSSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 274. RUSSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 275. RUSSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 276. RUSSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 277. RUSSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 278. RUSSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 279. RUSSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 280. RUSSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 281. RUSSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 282. RUSSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 283. RUSSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 284. RUSSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 285. RUSSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 286. RUSSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 287. RUSSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 288. RUSSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 289. ITALY MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 290. ITALY MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 291. ITALY MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 292. ITALY MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 293. ITALY MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 294. ITALY MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 295. ITALY MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 296. ITALY MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 297. ITALY MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 298. ITALY MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 299. ITALY MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 300. ITALY MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 301. ITALY MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 302. ITALY MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 303. ITALY MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 304. ITALY MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 305. ITALY MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 306. ITALY MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 307. SPAIN MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 308. SPAIN MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 309. SPAIN MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 310. SPAIN MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 311. SPAIN MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 312. SPAIN MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 313. SPAIN MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 314. SPAIN MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 315. SPAIN MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 316. SPAIN MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 317. SPAIN MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 318. SPAIN MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 319. SPAIN MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 320. SPAIN MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 321. SPAIN MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 32

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Malignant Mesothelioma market report include:
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd.
  • Pfizer Inc.
  • Johnson & Johnson
  • Novartis AG
  • Takeda Pharmaceutical Company Limited
  • Sanofi S.A.

Table Information

Report AttributeDetails
No. of Pages186
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 905.16 Million
Forecasted Market Value ( USD ) by 2030 $ 1340 Million
Compound Annual Growth Rate8.3%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Malignant Mesothelioma Market Report 2025 - Product Image

Malignant Mesothelioma Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Malignant Mesothelioma Drug Pipeline Analysis Report 2025 - Product Image

Malignant Mesothelioma Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • 200 Pages
  • Global
From
Malignant Pleural Mesothelioma Market (2024 Edition): Analysis By Drug Type, By Route of Administration, By Distribution Channel, By Region, By Country: Market Insights and Forecast (2020-2030) - Product Image

Malignant Pleural Mesothelioma Market (2024 Edition): Analysis By Drug Type, By Route of Administration, By Distribution Channel, By Region, By Country: Market Insights and Forecast (2020-2030)

  • Report
  • 259 Pages
  • Global
From
Malignant Mesothelioma - Global Strategic Business Report - Product Image

Malignant Mesothelioma - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From
Mesothelioma Drug Pipeline Analysis Report 2025 - Product Image

Mesothelioma Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • 200 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.